FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761639206> ?p ?o ?g. }

• W2761639206 endingPage "114735" @default.
• W2761639206 startingPage "114722" @default.
• W2761639206 abstract "// Phillip M. Galbo Jr 1 , Michael J. Ciesielski 1, 5, 6 , Sheila Figel 1 , Orla Maguire 2 , Jingxin Qiu 3 , Laura Wiltsie 4, 6 , Hans Minderman 2 and Robert A. Fenstermaker 1, 5, 6 1 Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, New York, 14263 USA 2 Flow and Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York, 14263 USA 3 Pathology, Roswell Park Cancer Institute, Buffalo, New York, 14263 USA 4 Pediatrics, Roswell Park Cancer Institute, Buffalo, New York, 14263 USA 5 Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, 14263 USA 6 Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, New York, 14214 USA Correspondence to: Robert A. Fenstermaker, email: robert.fenstermaker@roswellpark.org Keywords: exosome; glial fibrillary acidic protein; glioblastoma; survivin; vaccine Received: July 27, 2017     Accepted: September 08, 2017     Published: October 10, 2017 ABSTRACT Glioma cells release exosomes in culture and into the extracellular matrix in vivo . These nanobodies transport an array of biomolecules and are capable of mediating cell-cell communication. Circulating exosomes in cancer patients may be indicative of disease status and response to therapy. The inhibitor of apoptosis protein (IAP) survivin (SVN) promotes cancer cell proliferation, local immune suppression and resistance to chemotherapy and it is a potential cancer biomarker. We used imaging flow cytometry to perform quantitative measurements of circulating SVN+ exosomes in the serum of malignant glioma patients undergoing investigational treatment with an anti-survivin vaccine (SurVaxM). Serum from glioma patients contained abundant CD9+ exosomes with both SVN and glial fibrillary acidic protein (GFAP) on their surface. Survivin and GFAP were evaluated both independently and together as possible tumor markers on CD9+ exosomes. Patients with longer time to tumor progression generally exhibited a decrease in circulating CD9+/SVN+ and CD9+/GFAP+/SVN+ exosomes immediately following survivin vaccination; whereas, those with early tumor progression had an increase in exosomes, despite anti-survivin immunotherapy. Serum from non-cancer healthy control individuals had very few detectable CD9+/GFAP+/SVN+ exosomes, although CD9+/GFAP+ exosomes were detectable in small numbers. This study demonstrates that patients with malignant gliomas have CD9+/GFAP+/SVN+ and CD9+/SVN+ exosomes that are released into the circulation and that early reductions in their numbers following anti-survivin immunotherapy might be associated with longer progression-free survival." @default.
• W2761639206 created "2017-10-20" @default.
• W2761639206 creator A5014024833 @default.
• W2761639206 creator A5018198056 @default.
• W2761639206 creator A5018341423 @default.
• W2761639206 creator A5033083387 @default.
• W2761639206 creator A5036910737 @default.
• W2761639206 creator A5053202206 @default.
• W2761639206 creator A5071938741 @default.
• W2761639206 creator A5072903686 @default.
• W2761639206 date "2017-10-10" @default.
• W2761639206 modified "2023-10-09" @default.
• W2761639206 title "Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination" @default.
• W2761639206 cites W1521397874 @default.
• W2761639206 cites W1602732985 @default.
• W2761639206 cites W1662899239 @default.
• W2761639206 cites W1877686344 @default.
• W2761639206 cites W1892252295 @default.
• W2761639206 cites W1893157084 @default.
• W2761639206 cites W1930737617 @default.
• W2761639206 cites W1964517239 @default.
• W2761639206 cites W1969347718 @default.
• W2761639206 cites W1970420774 @default.
• W2761639206 cites W1975320047 @default.
• W2761639206 cites W1979177187 @default.
• W2761639206 cites W1989603382 @default.
• W2761639206 cites W1994547407 @default.
• W2761639206 cites W1995257401 @default.
• W2761639206 cites W1999206667 @default.
• W2761639206 cites W2005742227 @default.
• W2761639206 cites W2012893265 @default.
• W2761639206 cites W2014869316 @default.
• W2761639206 cites W2018114565 @default.
• W2761639206 cites W2030701238 @default.
• W2761639206 cites W2032220418 @default.
• W2761639206 cites W2038363115 @default.
• W2761639206 cites W2039326270 @default.
• W2761639206 cites W2049186060 @default.
• W2761639206 cites W2053844022 @default.
• W2761639206 cites W2055169742 @default.
• W2761639206 cites W2056371902 @default.
• W2761639206 cites W2065776374 @default.
• W2761639206 cites W2068717924 @default.
• W2761639206 cites W2073942032 @default.
• W2761639206 cites W2081124475 @default.
• W2761639206 cites W2086523179 @default.
• W2761639206 cites W2086601270 @default.
• W2761639206 cites W2087487150 @default.
• W2761639206 cites W2095508526 @default.
• W2761639206 cites W2096712415 @default.
• W2761639206 cites W2107705644 @default.
• W2761639206 cites W2117582353 @default.
• W2761639206 cites W2140156946 @default.
• W2761639206 cites W2151442912 @default.
• W2761639206 cites W2152140063 @default.
• W2761639206 cites W2154021054 @default.
• W2761639206 cites W2161959295 @default.
• W2761639206 cites W2163633941 @default.
• W2761639206 cites W2175266268 @default.
• W2761639206 cites W2232550471 @default.
• W2761639206 cites W2244557822 @default.
• W2761639206 cites W2295603197 @default.
• W2761639206 cites W2510141057 @default.
• W2761639206 cites W2534500404 @default.
• W2761639206 cites W2554880605 @default.
• W2761639206 cites W2564038538 @default.
• W2761639206 cites W2611295098 @default.
• W2761639206 doi "https://doi.org/10.18632/oncotarget.21773" @default.
• W2761639206 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5777727" @default.
• W2761639206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29383115" @default.
• W2761639206 hasPublicationYear "2017" @default.
• W2761639206 type Work @default.
• W2761639206 sameAs 2761639206 @default.
• W2761639206 citedByCount "42" @default.
• W2761639206 countsByYear W27616392062018 @default.
• W2761639206 countsByYear W27616392062019 @default.
• W2761639206 countsByYear W27616392062020 @default.
• W2761639206 countsByYear W27616392062021 @default.
• W2761639206 countsByYear W27616392062022 @default.
• W2761639206 countsByYear W27616392062023 @default.
• W2761639206 crossrefType "journal-article" @default.
• W2761639206 hasAuthorship W2761639206A5014024833 @default.
• W2761639206 hasAuthorship W2761639206A5018198056 @default.
• W2761639206 hasAuthorship W2761639206A5018341423 @default.
• W2761639206 hasAuthorship W2761639206A5033083387 @default.
• W2761639206 hasAuthorship W2761639206A5036910737 @default.
• W2761639206 hasAuthorship W2761639206A5053202206 @default.
• W2761639206 hasAuthorship W2761639206A5071938741 @default.
• W2761639206 hasAuthorship W2761639206A5072903686 @default.
• W2761639206 hasBestOaLocation W27616392061 @default.
• W2761639206 hasConcept C104317684 @default.
• W2761639206 hasConcept C121608353 @default.
• W2761639206 hasConcept C126322002 @default.
• W2761639206 hasConcept C142724271 @default.
• W2761639206 hasConcept C143998085 @default.
• W2761639206 hasConcept C145059251 @default.
• W2761639206 hasConcept C203014093 @default.
• W2761639206 hasConcept C20518536 @default.

• next